CervoMed (DE:DP8)
FRANKFURT:DP8
DP8 Stock Chart & Stats
€3.22
-€0.06(-2.68%)
At close: 4:00 PM EST
€3.22
-€0.06(-2.68%)
Day’s Range― - ―
52-Week Range€2.34 - €8.95
Previous CloseN/A
Volume0.00
Average Volume (3M)15.00
Market Cap
€23.91M
Enterprise Value€20.85M
Total Cash (Recent Filing)€12.92M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-0.29
Next Earnings
Aug 17, 2026EPS Estimate
-0.69Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.27
Shares Outstanding9,258,719
10 Day Avg. Volume0
30 Day Avg. Volume15
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)3.92
Price to Sales (P/S)0.00
P/FCF Ratio-3.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€17.54Price Target Upside444.73% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-2.31
Revenue Forecast (FY)€196.05K
Bulls Say, Bears Say
Bulls Say
Biomarker-driven Patient SelectionIdentification of a plasma biomarker to exclude patients with Alzheimer’s co-pathology allows enrichment of the pivotal trial population and increases the chance of demonstrating meaningful cognitive benefit.
Manufacturing Stability And Intellectual PropertyA stable crystal form and single-step crystallization enable scalable manufacturing, improve drug stability and may support novel patent claims that could extend exclusivity.
Regulatory And Trial DesignRegulatory alignment with the FDA on primary endpoint, patient selection, trial duration and size enables a single global randomized pivotal trial toward approval and reduces development uncertainty.
Bears Say
Cash Burn And Operating LossesReported widening net losses and limited available cash highlight ongoing cash burn that may necessitate further fundraising to sustain development activities.
Execution Risk From Funding ShortfallLimited cash relative to projected operating needs raises the risk of delays or incomplete execution of the Phase 3 program if additional funding is not obtained.
Financing Dependency For Phase 3 StartAdvancement into the pivotal trial depends on securing additional financing, creating a risk that the Phase 3 program cannot commence without new capital.
CervoMed News
DP8 FAQ
What was CervoMed’s price range in the past 12 months?
CervoMed lowest stock price was €2.34 and its highest was €8.95 in the past 12 months.
What is CervoMed’s market cap?
CervoMed’s market cap is €23.91M.
When is CervoMed’s upcoming earnings report date?
CervoMed’s upcoming earnings report date is Aug 17, 2026 which is in 75 days.
How were CervoMed’s earnings last quarter?
CervoMed released its earnings results on May 18, 2026. The company reported -€0.739 earnings per share for the quarter, missing the consensus estimate of -€0.676 by -€0.064.
Is CervoMed overvalued?
According to Wall Street analysts CervoMed’s price is currently Undervalued.
Does CervoMed pay dividends?
CervoMed does not currently pay dividends.
What is CervoMed’s EPS estimate?
CervoMed’s EPS estimate is -0.69.
How many shares outstanding does CervoMed have?
CervoMed has 9,258,719 shares outstanding.
What happened to CervoMed’s price movement after its last earnings report?
CervoMed reported an EPS of -€0.739 in its last earnings report, missing expectations of -€0.676. Following the earnings report the stock price went down -9.15%.
Which hedge fund is a major shareholder of CervoMed?
Currently, no hedge funds are holding shares in DE:DP8
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CervoMed
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.
DP8 Stock 12 Month Forecast
Average Price Target
€17.54
▲(444.73% Upside)
Technical Analysis
X4 Pharmaceuticals
―
ABVC BioPharma
―
Jasper Therapeutics
―
Prelude Therapeutics
―
Estrella Immunopharma
―
Options Prices
Currently, No data available
---